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Abstract 
Depression has been linked to Alzheimer’s disease (AD) as either an increased risk factor for its 
development or as a prodromal symptom. The neurobiological basis for such association, however, 
remains poorly understood. Numerous studies have examined whether changes in amyloid beta (Aβ) 
metabolism, which has been implicated in AD, are also found in depression. In this paper, we investigated 
the relationship between depressive symptoms and cerebrospinal fluid (CSF) Aβ indices, in healthy 
cognitively normal elderly with late-life major depression (LLMD) and controls, by using a longitudinal 
approach, which is a novel contribution to the literature. Significantly lower levels of CSF Aβ42 were 
observed in the LLMD group at baseline and were associated with more depressive symptoms. During the 
longitudinal follow up, the depressed group remained cognitively unchanged, but was significantly less 
depressed than at baseline. A greater improvement in depressive symptoms was associated with increases 
in CSF Aβ42 levels in both groups. Increases in CSF Aβ42 and Aβ40 were also associated with increased 
CSF total tau. Our results suggest that LLMD may be associated with state-dependent effects of CSF 
Aβ42 levels. Future studies should determine if the association reflects state-dependent changes in 
neuronal activity in depression.
 
Introduction 
Several lines of evidence from epidemiological, case-control and longitudinal studies provide 
support for an association between depression or depressive symptoms, and an increased risk for 
dementia and Alzheimer's disease (AD), or for depression as a prodromal state of AD (Jorm, 2001; 
Osorio, Gumb, & Pomara, 2014). This relationship has been described not only for late onset depression, 
but also for depression starting earlier in life (Byers & Yaffe, 2011). In a longitudinal study conducted by 
Wilson and colleagues (2002) in cognitively normal elderly, increases in the number of depressive 
symptoms at baseline were associated with a 19% increased risk of AD, on average, during a 7-year 
longitudinal follow-up period. Yet puzzlingly there have also been results that do not support such an 
association (Beck et al., 2009; Richard et al., 2013), thereby highlighting the possible etiological 
heterogeneity of depression with respect to its association with AD, and the need for further study.  
Although the neurobiological mechanisms underlying the association between AD and depression 
are not yet clear, it is possible that there may be a common disturbance in Amyloid Beta (Aβ) metabolism 
(Pomara and Doraiswamy, 2003) in both conditions. Studies conducted by our group and others (Pomara 
et al., 2006; 2012) have highlighted abnormalities in Aβ40 or Aβ42 levels or their ratios, in plasma or 
serum, in individuals with depression. Analogously, a relatively smaller number of investigations have 
also reported changes in cerebrospinal fluid (CSF) Aβ concentration or brain amyloid burden using PET 
imaging in individuals with depression or depressive symptoms, albeit with conflicting results (e.g. 
Dinniz, Teizeira, Machado-Vieira, Talib, Radanovic, Gattaz, & Forlenza, 2014; Gudmundsson, Skoog, 
Waern, Blennow, Palsson, Rosengren, & Gustafson, 2007; Madsen et al., 2012; Pomara et al., 2012; 
Yasuno et al., 2016).  
 Methodological differences , however, may be at the root of these differences in results, 
including heterogeneity in the studied populations, including sometimes presence of individuals with 
MCI(Abbasowa & Heegaard, 2014; do Nascimento, Silva, Malloy-Diniz, Butters, & Diniz, 2015; 
Harrington, Lim, Gould, & Maruff, 2015; Osorio, Gumb, & Pomara, 2014). A separate issue pertains to 
the use of different approaches for detecting depression, with most relying on patients’ self-ratings, which 
may lack diagnostic specificity, and only a few studies employing structured interviews based on DSM 
diagnostic criteria. Finally, and critically, standardized pre-analytical and laboratory procedures for 
quantifying Aβ across centers were not employed (Abbasowa & Heegard, 2014). All of the existing 
studies have been limited to cross sectional comparisons based on a single Aβ determination; thus, it is 
not known if these abnormalities persist over time.  
To address these limitations, we conducted a longitudinal prospective study in depressed elderly 
andage-matched controls, all of whom were cognitively normal at baseline. All subjects were diagnosed 
using a structured interview as per DSM-4 criteria, and the same lab and immunoassay method with 
demonstrated sensitivity and reliability for Aβ determination was employed (see Methods). Our goal was 
to determine first whether LLMD and time (baseline to follow-up) had an effect on the Aβ levels; and 
second to determine whether any time-related change in Aβ was associated with changes in the severity 
of depressive symptoms. Additionally, analogous analyses were also carried out on CSF total-tau and p-
tau to gauge the possible emergence of neurodegeneration and neurofibrillary pathology, respectively, in 
the course of the longitudinal study. 
Methods 
This study was conducted in accordance with the Declaration of Helsinki. Approval for this study 
was received from the Nathan S. Kline Institute/Rockland Psychiatry Center Institutional Review Board 
(NKI/RPC IRB) and the NYU Langone Medical Center Institutional Review Board. All participants 
provided written informed consent before their participation. Ninety-one participants, aged 60 years and 
older, with an MMSE score of at least 28, completed a 3-year longitudinal study. At baseline, 51 of these 
individuals agreed to an optional lumbar puncture (LP). Three of these individuals were excluded for MRI 
findings, and an additional individual was excluded for an MMSE score below 28 (Table 1).  
Table 1. Baseline demographics of cognitively intact individuals with LLMD and aged-matched control 
subjects.  
Baseline (Mean(SD)) Statistical Analysis  
Control Group  
(N =19) 
LLMD Group  
(N=28) 
t df  p 
Age  68.1 (7.3) 66.5 (5.4) 0.84 45 0.41 
Education  16.7 (2.7) 16.5 (2.7) 0.27 44 0.79 
HAM-D Score  1.2 (1.9) 14.9 (8.8) 8.02 45 <.0001* 
MMSE Score  29.5 (0.5) 29.8 (0.6) 1.56 45 0.13 
CSF was obtained from 47 individuals (see Table 2), with late-life major depression group (LLMD; 
N=28) and age- and gender-matched control group (N=19), and again at the 3-year follow-up visit 
(LLMD group, N=19; control group, N=17). The analyses are limited to the follow-up group. CSF levels 
of Aβ42, Aβ40, total-tau (t-Tau) and p-tau were measured using previously established methods by 
board-certified laboratory technicians who were blinded to clinical data (Pomara et al. 2012). Participants 
underwent a comprehensive neuropsychological evaluation as well as a clinical evaluation that included 
the Hamilton Depression scale (HAM-D), at baseline and at follow-up. Pearson’s correlations were 
computed between Aβ indices and HAM-D scores. All statistical analysis was performed using SPSS 
statistical software package, version 22.0 for Windows (SPSS, Inc., Chicago).  
Table 2. HAM-D and CSF levels of Aβ42, Aβ40, total-tau (t-Tau) and p-tau at baseline and follow-up. 
LLMD Controls 
 Baseline 
Mean (SD) 
Follow-Up 
Mean (SD) 
Baseline 
Mean (SD) 
Follow-up 
Mean (SD) 
HAM-D 14.9 (8.8) 8.74 (8.1) 1.2 (1.9) 2.24 (6.01) 
CSF Aâ42 231.42 (117.64) 261.05 (148.01) 335.94 (187.71) 279.29 (118.17) 
CSF Aâ40 5285.84 (2408.60) 3728.47 (1379.17) 6550.29 (2799.71) 4020.06 (1145.78) 
T-tau 254.33 (122.39) 277.33 (111.98) 343.59 (152.59) 365.71 (136.17) 
P-tau 48.68 (30.76) 49.63 (34.86) 48.93 (25.87) 51.12 (18.12) 
 
Results 
To evaluate if clinical group (LLMD and control) and time had an effect on the Aβ levels, we 
conducted two 2x2 repeated measures ANOVAs (GROUP, between-subjects; and TIME, within-subjects) 
on Aβ40 and Aβ42. A main effect of time was detected on Aβ40, p<.001, showing a decline in levels 
between baseline (5882.94, SD=2631.67) and follow-up (3866.17, SD=1264.98); no main effect of 
LLMD (p=.202) or an interaction were observed (p=.146). When we examined Aβ42, in contrast, we 
found a significant interaction (p=.050), suggesting that although depressed individuals had lower levels 
at baseline, this difference was not present at follow-up (see Figure 1).  
Figure 1. Three year follow-up of cognitively intact individuals with LLMD and control subjects. a) 
HAM-D scores in the LLMD group and control subjects at baseline and 3-year follow-up. There was a 
significant decrease in HAM-D score in the LLMD group at the 3-year follow-up as previously reported 
in Hashimoto et al. (2011). b) CSF Aβ42 levels in the LLMD group and control subjects at baseline and 
3-year follow-up. There was a significant interaction between Aβ42 levels and time.  
 
To evaluate whether changes in Aβ were linked with changes in the severity of depressive 
symptoms, we carried out Pearson’s bivariate correlations between Aβ and Ham-D levels, using change 
in Ham-D scores and change  in CSF Aβ concentration (follow-up – baseline). The reductions in 
depressive symptoms observed over time were significantly correlated with increases in CSF Aβ42 levels, 
both in the entire cohort (r= -.451, p=.006) and within the LLMD group (r=-.547, p=.015), specifically, 
but not in the control group (p=.809). The same relationship was not significant with Aβ40 (p’s > .200). 
To examine whether changes in Aβ42 were related to t-tau and p-tau, Pearson’s bivariate 
correlations were conducted between change scores in the LLMD group, as referenced above. 
Comparisons of the follow-up to baseline levels, revealed a significant correlation between CSF Aβ42 
levels and T-Tau (r=.557, p=.016). A significant correlation was found with CSF Aβ40 levels as well 
(r=.586, p=.011). Thus, increases t-tau in the LLMD group, over time, were associated with increases in 
both CSF Aβ42 and CSF Aβ40. The same significant correlations were not found between p-tau and CSF 
Aβ42 or CSF Aβ40 (p’s >.700).  
Discussion 
This is the first prospective longitudinal study to have examined the relationship between 
different phases of depression and CSF Aβ indices in cognitively intact elderly. Participants were 
examined at baseline who either had LLMD or were controls, and CSF Aβ42 and Aβ40 levels were found 
to be lower in this depressed group compared to controls (Pomara et al., 2012). Over the 3-year 
longitudinal study, we observed that the depressed group became significantly less depressed than at 
baseline. At the same time, we also noted that the difference in CSF Aβ levels between groups was no 
longer significant. Consistently with this finding, we observed that the degree of change in the severity of 
depression in all participants over the life of the study was correlated with change in Aβ42. All in all, 
these findings suggest the possibility of a state-dependent association between CSF Aβ levels, especially 
Aβ42, and depressive symptoms. This would indicate that the metabolic disturbances leading to Aβ 
abnormalities in LLMD individuals are reversible rather than fixed, and possibly treatable.  
 Additionally, the possibility that the numerical increase in soluble CSF Aβ42 level, which we observed 
in the MDD group, emerged in the presence of increased brain amyloid burden cannot be excluded since 
CSF Aβ42 levels in the depressed group were still numerically lower than in controls at year three.  
We also found that increases in CSF Aβ42 and Aβ40 from baseline during the 3-year longitudinal 
follow-up were associated with increases in t-tau. Increases in tau have been associated with progressive 
cognitive decline and AD, and have been ascribed to increase neuronal and axonal degeneration. 
However, the correlations with tau in this study were not associated with progressive cognitive decline or 
the emergence of AD and the increases remained within the normal range of CSF t-tau concentrations. 
This raises the possibility that other factors may have contributed to this relationship. Several lines of 
evidence from preclinical studies suggest that increased neuronal activity can result in increased release of 
Aβ peptides as well as tau (Yamanda et al., 2014). Thus, these results are consistent with the hypothesis 
that state-dependent changes in neuronal activity may underlie the aforementioned association. 
Results from recent investigations of resting fMRI connectivity in depression suggest a complex 
pattern of neuronal activity in LLMD with reductions in brain functional connectivity in the cognitive 
network as well as increases in the default mode network (DMN) (Kenny, O’Brien, Cousins, Richardson, 
Thomas, Firbank, & Blamire, 2010). However, resting fMRI connectivity studies in individuals with late-
life depression, which are most pertinent to this report, have consistently described reductions in the 
default mode network connectivity (Wu et al. 2011, Alexopoulos et al. 2012). Human studies using CBF 
and FDG-PET report reductions in cortical neuronal activity in the depressive phase of unipolar 
depression and improvement with remission (Nikolaus, Larisch, Vosberg, & Muller-Gartner, 2000). 
These results are consistent with our hypothesis that state-dependent effects on neuronal activity may 
underlie the changes in CSF Aβ42 across different phases of depression. 
However, alternative hypotheses should be considered for the association between CSF 
Aβ42 and depressive symptoms including the possibility of state-dependent changes in 
oligomeric forms of Aβ in depression. These forms might have escaped detection by the  
electrochemiluminescence  technology  assay that we employed,  as was previously reported for 
the ELISA method (Englund et al., 2009; Stehn et al., 2005),  and they may have also masked 
epitopes of Aβ42 and Aβ40, resulting in their low levels. Thus increases in oligomeric forms of 
Aβ might have contributed to the low levels of CSF plasma Aβ42  and Aβ40 observed at baseline 
and to their association with more depressive symptoms. Conversely, their reduction during the 
longitudinal period was associated with higher CSF Aβ42 levels and reduced depression. 
Thus future studies should also examine oligomeric forms of CSF Aβ in elderly 
depressives. Additionally, since none of the existing investigations simultaneously determined 
brain amyloid burden by PET or CSF Aβ and tau levels, future studies should therefore also 
examine the relationship between these AD biomarkers and measures of neuronal and functional 
connectivity in elderly depressives, both in the depressive phase of the illness and following 
remission. 
There is also emerging evidence that changes in the quality of sleep and its architecture, 
which are commonly disrupted in depression, can result in increased brain amyloid burden 
through effects in neuronal activity and glymphatic clearance. However, so far none of these 
studies have been conducted in depression. Thus it will important for future studies to determine 
if these factors contribute to altered Aβ dynamics in elderly depressives. 
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